- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04712903
Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer (CANTABRICO)
A Phase IIIB, Single Arm Study, of Durvalumab in Combination With Platinum-Etoposide for Untreated Patients With Extensive-Stage Small Cell Lung Cancer Reflecting Real World Clinical Practice in Spain (CANTABRICO).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This trial will provide an opportunity to further evaluate the safety profile and efficacy of durvalumab + EP in patient population that is reflective of real-world clinical practice, Durvalumab will be concurrently administered with first-line chemotherapy (EP) on an every 3 week (q3w) schedule for 4 to 6 cycles, and will continue to be administered as monotherapy post-chemotherapy on an every 4 week (q4w) schedule until confirmed progressive disease (PD) or unacceptable toxicity.
Prophylactic cranial irradiation (PCI) is allowed in patients showing complete or partial responses after the durvalumab + EP combination cycles, at the discretion of the investigator according to their local clinical practice.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
A Coruna, Spain, 15006
- Research Site
-
Alicante, Spain, 03010
- Research Site
-
Badajoz, Spain, 6006
- Research Site
-
Badalona, Spain, 08916
- Research Site
-
Barcelona, Spain, 08036
- Research Site
-
Barcelona, Spain, ?08041
- Research Site
-
Barcelona, Spain, 08908
- Research Site
-
Barcelona, Spain, 8003
- Research Site
-
Castellon de la Plana, Spain, 12004
- Research Site
-
Córdoba, Spain, 14004
- Research Site
-
Galdakao, Spain, 48960
- Research Site
-
Granada, Spain, 18014
- Research Site
-
Jaén, Spain, 23007
- Research Site
-
La Laguna, Spain, 38320
- Research Site
-
León, Spain, 24071
- Research Site
-
Madrid, Spain, 28034
- Research Site
-
Madrid, Spain, 28041
- Research Site
-
Madrid, Spain, 28040
- Research Site
-
Madrid, Spain, 28027
- Research Site
-
Majadahonda, Spain, 28222
- Research Site
-
Mataro, Spain, 08304
- Research Site
-
Murcia, Spain, 30008
- Research Site
-
Málaga, Spain, 29011
- Research Site
-
Ourense, Spain, 32005
- Research Site
-
Oviedo, Spain, 33011
- Research Site
-
Palma, Spain, 07198
- Research Site
-
Reus,Tarragona, Spain, 43204
- Research Site
-
San Sebastián, Spain, 20014
- Research Site
-
Santander, Spain, 39008
- Research Site
-
Santiago de Compostela, Spain, 15706
- Research Site
-
Toledo, Spain, 45004
- Research Site
-
Valencia, Spain, 46026
- Research Site
-
Valladolid, Spain, 47003
- Research Site
-
Zaragoza, Spain, 50009
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically or cytologically documented Small cell Lung Cancer with extensive disease.
- Patients who had received chemoradiotherapy for LS-SCLC and have experienced a treatment-free interval of at least 6 months since last chemotherapy, radiotherapy, or chemoradiotherapy cycle, can be included under investigator criteria.
- Brain metastases; must be asymptomatic or have been treated at least 2 weeks prior to study treatment and are currently receiving 10 mg/day or less of prednisone or equivalent.
- Patients must be considered suitable to receive a platinum-based chemotherapy regimen as 1st line treatment for ES-SCLC.
- ECOG Performance Status of 0-2 at enrolment.
- No prior exposure to immune-mediated therapy for cancer.
- Adequate hematologic and organ function.
- Life expectancy of at least 12 weeks.
- Body weight >30 kg.
Exclusion Criteria:
- Any history of radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy (except paliative care outside of the chest).
- Paraneoplastic syndrome of autoimmune nature, requiring systemic treatment or clinical symptomatology suggesting worsening of PNS
- Active infection including tuberculosis, HIV, hepatitis B anc C
- Active or prior documented autoimmune or inflammatory disorders
- Uncontrolled intercurrent illness, including but not limited to interstitial lung disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Durvalumab in Combination with Platinum-Etoposide
Durvalumab 1500 mg via IV infusion will be concurrently administered with first-line chemotherapy (EP) on an every 3 week (q3w) schedule for 4 to 6 cycles, and will continue to be administered post-chemotherapy on an every 4 week (q4w) schedule until confirmed progressive disease (PD) or unacceptable toxicity.
|
Durvalumab 1500 mg via IV infusion over 60 minutes on Day 1 of each cycle.
Cisplatin as an IV infusion per local standards (usually over 60 to 120 minutes on Day 1) of each cycle.
Etoposide sequentially administered per local standards (usually over 30 to 60 minutes IV infusion) on Days 1, 2, and 3 of each cycle.
Carboplatin as an IV infusion per local standards (usually over 30 to 60 minutes on Day 1) of each cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of grade ≥ 3 Adverse Events (AE)
Time Frame: Up to 18 months
|
Up to 18 months
|
Incidence of Immune Mediated Adverse Events (imAE).
Time Frame: Up to 18 months
|
Up to 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival (PFS).
Time Frame: Up to 18 months
|
PFS, defined as the time from initiation of study treatment to the first occurrence of disease progression or death from any cause, whichever occurs first.
PFS will be calculated based on disease status evaluated by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
|
Up to 18 months
|
PFS rate at 6 months (PFS6).
Time Frame: Up to 6 months
|
PFS at 6 months, defined as the proportion of participants remaining alive without disease progression at 6 months after initiation of study treatment.
|
Up to 6 months
|
PFS rate at 1 year (PFS12).
Time Frame: Up to 12 months
|
PFS at 1 year, defined as the proportion of participants remaining alive without disease progression at 1 year after initiation of study treatment.
|
Up to 12 months
|
Objective Response Rate (ORR): using site investigator assessments according to RECIST 1.1.
Time Frame: Up to 18 months
|
ORR, defined as the percentage of patients who attain complete response (CR) or partial response (PR) according to RECIST v1.
|
Up to 18 months
|
Duration of Response (DoR).
Time Frame: Up to 18 months
|
Duration of response (DOR), defined as the time from initial response to disease progression or death among patients who have experienced a CR or PR (unconfirmed) during the study.
Duration of response will be calculated based on disease status evaluated by the investigator according to RECIST v1.1.
|
Up to 18 months
|
DoR rate at 1 year (DoR12)
Time Frame: Up to 12 months
|
DoR at 1 year, defined as the proportion of participants having CR or PR (unconfirmed) at 1 year after initiation of study treatment.
|
Up to 12 months
|
Time to Treatment Discontinuation (TTD).
Time Frame: Up to 18 months
|
Defined as the time in months between first and last study treatment dose.
|
Up to 18 months
|
Overal Survival (OS).
Time Frame: Up to 18 months
|
OS, defined as the time from initiation of study treatment to death from any cause.
|
Up to 18 months
|
OS rate at 6 months.
Time Frame: Up to 6 months
|
OS at 6 months, defined as the proportion of participants remaining alive at 6 months after initiation of study treatment.
|
Up to 6 months
|
OS rate at 1 year.
Time Frame: Up to 12 months
|
OS at 1 year, defined as the proportion of participants remaining alive at 1 year after initiation of study treatment.
|
Up to 12 months
|
OS rate at 18 months.
Time Frame: Up to 18 months
|
OS at 18 months, defined as the proportion of participants remaining alive at 18 months after initiation of study treatment.
|
Up to 18 months
|
Change from baseline in symptoms and quality of life as assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items (EORTC QLQ-C30) and Questionnaire-Lung Cancer 13 (EORTC QLQ-LC13).
Time Frame: Up to 18 months
|
Up to 18 months
|
|
Changes from baseline in PRO-CTCAE.
Time Frame: Up to 18 months
|
Up to 18 months
|
|
Number of visits to oncology service, emergency visits, outpatient visits, imaging tests and biopsy-related procedures and number and length of hospitalizations.
Time Frame: Up to 18 months
|
Up to 18 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dolores Isla, M.D., Hospital Clínico Lozano Blesa, Zaragoza
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Carboplatin
- Etoposide
- Durvalumab
Other Study ID Numbers
- D419QC00005
- 2020-002328-35 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Cell Lung Carcinoma Extensive Disease
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingPlatinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Extensive Stage Lung Small Cell Carcinoma | Refractory Extensive Stage Lung Small Cell CarcinomaUnited States
-
Zhejiang Cancer HospitalRecruitingExtensive Stage Lung Small Cell CancerChina
-
Jonsson Comprehensive Cancer CenterPfizer; Translational Research in OncologyRecruitingRecurrent Extensive Stage Small Cell Lung Carcinoma | Refractory Extensive Stage Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedExtensive Stage Lung Small Cell CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)NRG OncologyRecruitingExtensive Stage Lung Small Cell CarcinomaUnited States
-
European Lung Cancer Working PartyCompletedSmall Cell Lung Carcinoma, Extensive DiseaseBelgium, France, Greece, Spain
-
Chugai PharmaceuticalJapan Lung Cancer SocietyCompletedNon-small Cell Lung Cancer | Extensive Disease Small Cell Lung CancerJapan
-
National Cancer Institute (NCI)Active, not recruitingExtensive Stage Lung Small Cell CarcinomaUnited States
Clinical Trials on Durvalumab
-
AstraZenecaKappa SantéRecruiting
-
Yonsei UniversityRecruitingPotentially Resectable Stage II/IIIa NSCLCKorea, Republic of
-
Academic Thoracic Oncology Medical Investigators...AstraZenecaCompletedNon-Small Cell Lung Cancer NSCLCUnited States
-
Yonsei UniversityCompleted
-
NSABP Foundation IncCompletedRectal CancerUnited States
-
Hark Kyun KimRecruiting
-
Oslo University HospitalAstraZenecaActive, not recruitingCancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage IIINorway, Finland, Lithuania, Estonia
-
MedImmune LLCCompletedAdvanced Solid TumorsUnited States, France, Spain, Switzerland
-
Yonsei UniversityNot yet recruitingNon Small Cell Lung CancerKorea, Republic of
-
AstraZenecaCompleted